Phase II Study of Asparagine-Glycine-Arginine-Human Tumor Necrosis Factor α, a Selective Vascular Targeting Agent, in Previously Treated Patients With Malignant Pleural Mesothelioma
Phase II Study of Asparagine-Glycine-Arginine-Human Tumor Necrosis Factor α, a Selective Vascular Targeting Agent, in Previously Treated Patients With Malignant Pleural Mesothelioma
复制标题
DOI：
10.1200/jco.2009.27.3649
复制
发表时间：
2010-05-20
影响因子：
45.3
通讯作者：
Bordignon, Claudio
中科院分区：
文献类型：
--
作者：
Gregorc, Vanesa;Zucali, Paolo A.;Bordignon, Claudio
目的NGR-hTNF 由与肿瘤归巢肽天冬酰胺-甘氨酸-精氨酸 (NGR) 融合的人肿瘤坏死因子 α (hTNF-α) 组成，能够选择性结合肿瘤血管上过表达的氨肽酶 N 同种型。血管丰富是恶性胸膜间皮瘤（MPM）的一个突出且预后不良的特征。目前，对于一线培美曲塞治疗方案失败的 MPM 患者，尚无标准选择。我们探讨了 NGR-hTNF 在这种情况下的安全性和有效性。患者和方法符合条件的患者已进行放射学记录的肿瘤进展和体力状态
PurposeNGR-hTNF consists of human tumor necrosis factor alpha (hTNF-alpha) fused to the tumor-homing peptide asparagine-glycine-arginine (NGR) able to selectively bind an aminopeptidase N isoform overexpressed on tumor blood vessels. Hypervascularity is a prominent and poor-prognosis feature of malignant pleural mesothelioma (MPM). Currently, there are no standard options for patients with MPM who are failing a front-line pemetrexed-based regimen. We explored safety and efficacy of NGR-hTNF in this setting.Patients and MethodsEligible patients had radiologically documented tumor progression and performance status